Market Research Report
Global Overactive Bladder Treatment Market - 2019-2026
|Published by||DataM Intelligence||Product code||879320|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Overactive Bladder Treatment Market - 2019-2026|
|Published: June 1, 2019||Content info: 130-180 Pages||
The global overactive bladder treatment market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.
Overactive bladder is a group of urinary syndromes that are characterized by sudden, involuntary contraction of the muscle in the wall of the urinary bladder. This results in an immediate, compelling need to urinate that is difficult to suppress, even though the bladder may only contain a small amount of urine. Other symptoms include nocturia or urinary incontinence. Overactive bladder is a urological condition and not a disease and can be treated by therapies and prescribed drugs. Neurological disorders such as Parkinson's disease and multiple sclerosis can also cause overactive bladder. The condition is more prevalent in women than in men, and the prevalence rate is directly proportional to age, i.e., the prevalence rate of the overactive bladder increases with the increase in age.
Growth in the geriatric population is boosting the market growth as a rise in age is directly proportional to rise in prevalence of overactive bladder condition.
The market is driven by a rise in the prevalence of overactive bladder, growth in the geriatric population, an increase in neurological disorders and obesity, and an increase in R&D by major market players.
According to the United Nations (UN), there were around 962 million people aged 60 years or over in 2017. The number of persons aged 80 years or over are projected to increase more than threefold between 2017 and 2050, rising from 137 million to 425 million. Urinary incontinence and nocturia generally increase with aging. Overactive bladder has a significant negative impact on the quality of life and health of the aged population.
Furthermore, prominent key market players and manufacturers are continuously working on new research and development and increasing investments to develop new drugs and therapies such as neuromuscular blocking agents with innovative mechanism of actions. A rise in investment and R&D boost market growth.
Lack of awareness and unfavorable side effects of some current treatment available are going to restrain the market in the forecast period.
Behavioral Intervention is expected to have the largest share in the market due to their high effectiveness and minimal/no side effects.
The global overactive bladder treatment market can be segmented by treatment type as Behavioral Intervention, Medication, Bladder Botox Treatment, Nerve Stimulation, and Surgery and by disease type as Idiopathic Overactive Bladder and Neurogenic Overactive Bladder.
Based on treatment type, Behavioral Intervention is expected to account for the largest market share over the period of forecast. Behavioral Intervention includes Education, Lifestyle and dietary modifications, Bladder training, Pelvic floor muscle therapy, and Voiding diaries. Behavioral interventions are the first choice in helping manage an overactive bladder. They are often useful, and they carry no side effects. These various techniques help in eliminating, reducing, and managing the overactive bladder condition.
Medication is expected to grow at the highest pace over the period of forecast. The most common group of drugs used to treat overactive bladder are anticholinergic drugs. These medications work by diminishing the activity of and relaxing the detrusor muscle. Some of the medicines used for the treatment of overactive bladder are Oxybutynin (Ditropan), Tolterodine (Detrol), Solifenacin (VESIcare), Darifenacin (Enablex) and Fesoterodine. Occasionally antidepressant medications are used for the treatment of overactive bladder.
Geographically, the global overactive bladder treatment market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.
North America is expected to account for the highest market share of the overactive bladder treatment market during the forecast period. This growth is attributed to the well-established healthcare industry in countries like U.S and Canada, highly favorable reimbursement scenarios by the government for the treatment of overactive bladder condition, growing prevalence of the disease with rising age, and the presence of major players in the region. According to the American Urological Association, around 30% of men and 40% of women in the US live with overactive bladder condition.
Some of the major key players in the market are Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical Industries Limited, Allergan plc, Mylan N.V., Endo International plc, Hisamitsu Pharmaceutical Co., Inc., Sanofi, Aurobindo Pharma Limited, Johnson & Johnson, Intas Pharmaceuticals Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., Medtronic plc, Cogentix Medical, Inc., Accord Healthcare Inc. and Alembic Pharmaceuticals Ltd.
Prominent key players are making efforts in launching consumer campaigns that aim to increase the awareness of this disorder among the people. For instance, in 2016, Medtronic plc launched NURO system that delivers percutaneous tibial neuromodulation (PTNM) for the treatment of overactive bladder (OAB) with symptoms of urinary urgency, urinary frequency, and urge incontinence. PTNM, a minimally invasive, periodic, office-based procedure, provides a measurable reduction in urinary frequency and urinary incontinence episodes following treatment without the side effects of medication. The NURO System delivers a gentle electrical pulse to the tibial nerve via an acupuncture-like needle placed in the skin near the ankle that is attached to a neurostimulator.
In November 2018, Hisamitsu Pharmaceutical Co., Inc. announced that it had acquired approval of manufacturing and marketing permit for OABLOK® PATCH in Taiwan that is a transdermal, overactive bladder treatment patch.
In April 2018, LABORIE Medical Technologies and Cogentix Medical announced the completion of the acquisition of Cogentix Medical by LABORIE Medical Technologies, whose product portfolio includes overactive bladder treatment.
Global Overactive Bladder Treatment Market Methodology and Scope